Castle Biosciences, Inc. (NASDAQ:CSTL) Short Interest Update

Castle Biosciences, Inc. (NASDAQ:CSTLGet Rating) was the recipient of a significant growth in short interest during the month of December. As of December 30th, there was short interest totalling 1,190,000 shares, a growth of 5.3% from the December 15th total of 1,130,000 shares. Approximately 4.9% of the company’s stock are short sold. Based on an average daily trading volume, of 200,900 shares, the short-interest ratio is currently 5.9 days.

Insider Buying and Selling

In related news, insider Derek J. Maetzold sold 3,833 shares of the stock in a transaction that occurred on Monday, December 5th. The stock was sold at an average price of $24.79, for a total value of $95,020.07. Following the transaction, the insider now owns 294,723 shares in the company, valued at $7,306,183.17. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Derek J. Maetzold sold 3,833 shares of the stock in a transaction that occurred on Monday, December 5th. The stock was sold at an average price of $24.79, for a total value of $95,020.07. Following the transaction, the insider now owns 294,723 shares in the company, valued at $7,306,183.17. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel Bradbury sold 7,704 shares of the stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $22.89, for a total value of $176,344.56. Following the completion of the transaction, the director now owns 199,539 shares in the company, valued at approximately $4,567,447.71. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,072 shares of company stock worth $507,358. Insiders own 7.30% of the company’s stock.

Hedge Funds Weigh In On Castle Biosciences

A number of hedge funds have recently modified their holdings of the stock. Point72 Hong Kong Ltd raised its stake in Castle Biosciences by 827.0% during the third quarter. Point72 Hong Kong Ltd now owns 1,168 shares of the company’s stock worth $30,000 after acquiring an additional 1,042 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Castle Biosciences by 61.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 1,821 shares of the company’s stock valued at $47,000 after purchasing an additional 691 shares during the last quarter. Lazard Asset Management LLC bought a new position in Castle Biosciences during the 1st quarter valued at about $57,000. Ensign Peak Advisors Inc grew its stake in Castle Biosciences by 247.2% during the third quarter. Ensign Peak Advisors Inc now owns 3,090 shares of the company’s stock worth $81,000 after buying an additional 2,200 shares during the last quarter. Finally, Captrust Financial Advisors grew its stake in Castle Biosciences by 762.2% during the second quarter. Captrust Financial Advisors now owns 4,018 shares of the company’s stock worth $88,000 after buying an additional 3,552 shares during the last quarter. 82.43% of the stock is owned by institutional investors and hedge funds.

Castle Biosciences Stock Down 1.7 %

Castle Biosciences stock opened at $26.55 on Wednesday. Castle Biosciences has a 12 month low of $15.58 and a 12 month high of $48.40. The stock has a market cap of $699.65 million, a price-to-earnings ratio of -12.95 and a beta of 1.00. The business has a 50 day moving average price of $23.66 and a two-hundred day moving average price of $25.60.

Castle Biosciences (NASDAQ:CSTLGet Rating) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.07). Castle Biosciences had a negative net margin of 42.79% and a negative return on equity of 11.87%. The business had revenue of $37.01 million during the quarter, compared to analyst estimates of $34.36 million. On average, analysts expect that Castle Biosciences will post -2.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CSTL has been the subject of a number of research analyst reports. Robert W. Baird cut their target price on shares of Castle Biosciences from $48.00 to $41.00 and set an “outperform” rating for the company in a research report on Thursday, November 3rd. Scotiabank started coverage on Castle Biosciences in a research report on Wednesday, January 4th. They issued a “sector outperform” rating and a $54.00 price target on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Castle Biosciences presently has a consensus rating of “Buy” and an average price target of $57.14.

About Castle Biosciences

(Get Rating)

Castle Biosciences, Inc, a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.

Featured Articles

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.